Finen 10 mg (Tablet)
Unit Price: ৳ 60.00 (1 x 10: ৳ 600.00)
Strip Price: ৳ 600.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Finerenone |
| Company | General pharmaceuticals ltd |
| Also available as |
Indications
- Reduce risk of eGFR decline
- Reduce risk of end-stage kidney disease
- Reduce risk of cardiovascular death
- Reduce risk of nonfatal myocardial infarction
- Reduce risk of hospitalization for heart failure
Pharmacology
- Mineralocorticoid receptor antagonist
- Selective antagonist of mineralocorticoid receptor
- Blocks MR mediated sodium reabsorption
- High potency and selectivity for the MR
- No relevant affinity for androgen, progesterone, estrogen and glucocorticoid receptors
- Stable blood pressure after initial decrease
- Complete absorption after oral administration
- Metabolism by CYP3A4 and CYP2C8
- Systemic blood clearance of about 25 L/h
Dosage & Administration
- Starting dosage of 10 mg or 20 mg orally once daily
- Dosage adjustment based on eGFR and serum potassium thresholds
- Tablets can be taken with or without food
- Crushed form available for patients unable to swallow whole tablets
- Recommended target daily dose of 20 mg
- Monitoring of serum potassium levels
- Missed dose instructions
Interaction
- Contraindicated with strong CYP3A4 inhibitors
- Increased exposure with moderate and weak CYP3A4 inhibitors
- Avoid concomitant use with strong or moderate CYP3A4 inducers
Contraindications
- Contraindicated in concomitant use with strong CYP3A4 inhibitors
- Contraindicated in patients with adrenal insufficiency
Side Effects
- Common adverse reactions include hyperkalemia, hypotension, and hyponatremia
Pregnancy & Lactation
- No available data on use in pregnancy
- Animal studies show developmental toxicity
- No data available on presence in human milk
Precautions & Warnings
- Can cause hyperkalemia
- Need for serum potassium and eGFR measurement before initiation
- Avoid if serum potassium is > 5.0 mEq/L
- More frequent monitoring for patients at risk for hyperkalemia
Use in Special Populations
- Safety and efficacy not established in patients below 18 years of age
- No dose adjustment required for geriatric patients
- Avoid use in patients with severe hepatic impairment
Overdose Effects
- Immediate interruption of treatment in case of suspected overdose
- Likely manifestation of overdose is hyperkalemia
- Standard treatment for hyperkalemia
Therapeutic Class
- Mineralocorticoid receptor antagonists
Storage Conditions
- Keep below 30°C temperature
- Away from light and moisture
- Keep out of the reach of children